/MNOV
MNOV Stock - MediciNova, Inc.
Healthcare|BiotechnologyNASDAQ
$1.43-1.38%
$0.02 (-1.38%) • Dec 19
69
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.59
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $1.57
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for MNOV
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.42 – $1.44
TARGET (TP)$1.64
STOP LOSS$1.32
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.48
52W High$2.20
52W Low$1.13
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | $1.00M | N/A | $4.04M | N/A |
| Gross Profit | N/A | $1.00M | N/A | $4.04M | N/A |
| Gross Margin | N/A | 100.0% | N/A | 100.0% | N/A |
| Operating Income | $-12,675,331 | $-9,900,265 | $-14,628,649 | $-10,215,812 | $-14,178,323 |
| Net Income | $-11,049,549 | $-8,571,516 | $-14,069,083 | $-10,134,252 | $-13,853,897 |
| Net Margin | N/A | -857.2% | N/A | -251.0% | N/A |
| EPS | $-0.23 | $-0.17 | $-0.29 | $-0.21 | $-0.31 |
Company Overview
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
MNOVBeat Rate
67%
Last 18 quarters
Avg Surprise
+22.2%
EPS vs Estimate
Beats / Misses
12/1
5 met exactly
Latest EPS
$-0.06
Q4 2025
EPS Surprise History
Q1 24
+50.0%
$-0.04vs$-0.08
Q2 24
-20.0%
$-0.06vs$-0.05
Q3 24
+16.7%
$-0.05vs$-0.06
Q4 24
0.0%
$-0.06vs$-0.06
Q1 25
0.0%
$-0.06vs$-0.06
Q2 25
+57.1%
$-0.06vs$-0.14
Q3 25
0.0%
$-0.07vs$-0.07
Q4 25
+25.0%
$-0.06vs$-0.08
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Feb 18, 2026 | $-0.10 | — | — | — |
Q4 2025 | Nov 12, 2025 | $-0.08 | $-0.06 | +25.0% | ✓ BEAT |
Q3 2025 | Aug 14, 2025 | $-0.07 | $-0.07 | 0.0% | = MET |
Q2 2025 | May 13, 2025 | $-0.14 | $-0.06 | +57.1% | ✓ BEAT |
Q1 2025 | Feb 19, 2025 | $-0.06 | $-0.06 | 0.0% | = MET |
Q4 2024 | Nov 13, 2024 | $-0.06 | $-0.06 | 0.0% | = MET |
Q3 2024 | Aug 8, 2024 | $-0.06 | $-0.05 | +16.7% | ✓ BEAT |
Q2 2024 | May 9, 2024 | $-0.05 | $-0.06 | -20.0% | ✗ MISS |
Q1 2024 | Feb 15, 2024 | $-0.08 | $-0.04 | +50.0% | ✓ BEAT |
Q4 2023 | Nov 9, 2023 | $-0.08 | $-0.01 | +87.5% | ✓ BEAT |
Q3 2023 | Aug 9, 2023 | $-0.07 | $-0.06 | +14.3% | ✓ BEAT |
Q2 2023 | May 11, 2023 | $-0.07 | $-0.06 | +14.3% | ✓ BEAT |
Q1 2023 | Mar 16, 2023 | $-0.09 | $-0.06 | +32.0% | ✓ BEAT |
Q4 2022 | Nov 10, 2022 | $-0.09 | $-0.07 | +22.2% | ✓ BEAT |
Q3 2022 | Aug 11, 2022 | $-0.08 | $-0.08 | 0.0% | = MET |
Q2 2022 | May 12, 2022 | $-0.09 | $-0.07 | +22.2% | ✓ BEAT |
Q1 2022 | Feb 16, 2022 | $-0.09 | $-0.04 | +55.6% | ✓ BEAT |
Q4 2021 | Nov 12, 2021 | $-0.09 | $-0.07 | +22.2% | ✓ BEAT |
Q3 2021 | Aug 12, 2021 | $-0.09 | $-0.09 | 0.0% | = MET |
Latest News
D. Boral Capital Maintains Buy on MediciNova, Maintains $9 Price Target
📈 PositiveBenzinga•Dec 18, 2025, 12:59 PM
MediciNova Completes Patient Enrollment in Mid-Stage Trial for Chemotherapy Nerve Damage
📈 PositiveBenzinga•Dec 18, 2025, 11:08 AM
D. Boral Capital Maintains Buy on MediciNova, Maintains $9 Price Target
📈 PositiveBenzinga•Dec 8, 2025, 04:16 PM
MediciNova Details COMBAT-ALS Baseline Characteristics, With Mean Age 60.6 And Mean Disease Duration 12.5 Months In 234 Randomized ALS Patients
➖ NeutralBenzinga•Dec 8, 2025, 11:09 AM
D. Boral Capital Maintains Buy on MediciNova, Maintains $9 Price Target
📈 PositiveBenzinga•Nov 4, 2025, 01:40 PM
MediciNova Completes Patient Enrollment In Its Phase 2 MN-001-NATG-202 Trial Of MN-001 (Tipelukast) For Hypertriglyceridemia And Non-alcoholic Fatty Liver Disease Due To Type 2 Diabetes, Top-Line Data Are Expected By The Summer Of 2026
📈 PositiveBenzinga•Nov 4, 2025, 12:09 PM
D. Boral Capital Maintains Buy on MediciNova, Maintains $9 Price Target
📈 PositiveBenzinga•Oct 31, 2025, 11:45 AM
Reported Earlier, MediciNova Reports Peer-Reviewed Study Showing MN-001 And MN-002 May Offer Novel Therapeutic Strategy For Atherosclerosis And Metabolic Disorders
📈 PositiveBenzinga•Oct 31, 2025, 08:01 AM
D. Boral Capital Maintains Buy on MediciNova, Maintains $9 Price Target
📈 PositiveBenzinga•Sep 22, 2025, 02:11 PM
MediciNova Completes Patient Enrollment In Phase 2/3 Clinical Trial, COMBAT-ALS For Treatment Of Amyotrophic Lateral Sclerosis
📈 PositiveBenzinga•Sep 22, 2025, 12:09 PM
MediciNova Issues Shareholder Update; Secures $30M SEPA To Advance R&D As COMBAT-ALS Trial Hits Enrollment Target; NIH-Funded EAP And MN-001 Diabetes Study Near Completion
📈 PositiveBenzinga•Sep 8, 2025, 01:12 PM
Reported Earlier, MediciNova Reaches Target Number Of Participants In COMBAT-ALS Clinical Trial Across Sites In US And Canada
📈 PositiveBenzinga•Aug 27, 2025, 06:06 AM
MediciNova Files Prospectus Relates To Offer, Sale Of Up To 25M Shares Of Common Stock By YA II PN, Ltd
➖ NeutralBenzinga•Aug 22, 2025, 08:27 PM
Frequently Asked Questions about MNOV
What is MNOV's current stock price?
MediciNova, Inc. (MNOV) is currently trading at $1.43 per share. The stock has moved -1.38% today.
What is the analyst price target for MNOV?
No analyst price targets are currently available for this stock.
What sector is MediciNova, Inc. in?
MediciNova, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is MNOV's market cap?
MediciNova, Inc. has a market capitalization of $0.07 billion, making it a small-cap company.
Does MNOV pay dividends?
No, MediciNova, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACRV
Acrivon Therapeutics, Inc. Common Stock
$2.16
Mkt Cap: $0.1B
BMEA
Biomea Fusion, Inc.
$1.40
Mkt Cap: $0.1B
CBUS
Cibus, Inc.
$1.71
Mkt Cap: $0.1B
FBIO
Fortress Biotech, Inc.
$3.54
Mkt Cap: $0.1B
IMUX
Immunic, Inc.
$0.57
Mkt Cap: $0.1B
PMVP
PMV Pharmaceuticals, Inc.
$1.24
Mkt Cap: $0.1B
RLMD
Relmada Therapeutics, Inc.
$4.35
Mkt Cap: $0.3B
TCRX
TScan Therapeutics, Inc.
$0.90
Mkt Cap: $0.1B
VXRT
Vaxart, Inc.
$0.35
Mkt Cap: $0.1B
XBIT
XBiotech Inc.
$2.50
Mkt Cap: $0.1B
Explore stocks similar to MNOV for comparison